NEB announces issuance of US patent for RNA-Seq technology

IPSWICH, Mass., May 5, 2015 /PRNewswire/ — New England Biolabs, Inc. (NEB®) announces the issuance of United States Patent Number 8,999,677, which describes a novel method for retaining valuable strand-specific information contained within RNA transcripts. The method, which involves the second strand being selectively removed through the excision of UTP molecules, is proving to be particularly useful for RNA-seq applications.

The ‘677 patent is the first issuance in a family of applications licensed exclusively to NEB from Max Planck Gesellschaft in 2012.  NEB has already introduced this technology to the market in products, such as its NEBNext® Ultra™ Directional RNA Library Prep Kit.  NEB has also sublicensed this technology to Illumina®, Inc.

NEBNext products are a series of highly pure and cost-effective reagents that facilitate DNA and RNA library preparation for next generation sequencing. The innovative NEBNext product line includes the Ultra Library Prep kits for DNA and RNA, which address the increasing need for fast and robust performance, and also allow the use of low-nanogram amounts of input DNA or RNA – ensuring optimal data quality with flexible workflows.

For more information on NEBNext Ultra Kits for library preparation, visit

About New England Biolabs
Established in the mid 1970’s, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics development. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit

Source – PRNewswire

Leave a Reply

Your email address will not be published. Required fields are marked *


Time limit is exhausted. Please reload CAPTCHA.